期刊文献+

托伐普坦联合新活素、呋塞米治疗难治性心力衰竭患者对心功能、肾功能及神经内分泌因子的影响 被引量:12

在线阅读 下载PDF
导出
摘要 目的观察托伐普坦联合新活素、呋塞米治疗难治性心力衰竭患者对心功能、肾功能及神经内分泌因子的影响。方法选择医院收治的难治性心力衰竭患者72例,随机分为观察组和对照组,每组36例。对照组予以常规西医治疗,观察组在对照组基础上予以托伐普坦联合新活素、呋塞米治疗,比较2组治疗前后心功能、肾功能、神经内分泌因子各项变化情况。结果治疗后,2组左室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)较治疗前降低,左心室射血分数(LVEF)、心脏指数(CI)较治疗前升高,且观察组降低或升高幅度大于对照组(P均<0.05);2组患者治疗前后肾功能各项指标比较差异均无统计学意义(P>0.05);治疗后,2组B型钠尿肽(BNP)、群体反应性抗体(PRA)、血管紧张素Ⅱ(AngⅡ)、内皮素(ET)、心房钠尿肽(ANP)、β-内咖啡水平较治疗前降低,且观察组降低幅度大于对照组(P均<0.05)。结论托伐普坦联合新活素、呋塞米治疗可有效改善难治性心力衰竭患者的心脏功能,调节神经内分泌因子水平,且不会增加肾脏负担,不会导致肾功能的恶化,治疗效果良好,值得推广应用。
作者 孙花梅
出处 《临床合理用药杂志》 2019年第32期25-26,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献9

二级参考文献71

  • 1ADAMS KF Jr, FONAROW GC, EMERMAN CL, et ol. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE) [J]. Am Heart J, 2005, 149(2) : 209-216.
  • 2PEACOCK WF, COSTANZO MR, de MARCO T, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry[J]. Cardiology, 2009, 113(1 ) : 12-19.
  • 3HASSELBLAD V, GATTIS STOUGH W, SHAH MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: Results of the ESCAPE trial[J]. Eur J Heart Fail, 2007, 9(10): 1064-1069.
  • 4UDELSON JE, MCGREW FA, FLORES E, et al. Multicenter, randomized, double- blind, placebo- controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction [J]. J Am Coil Cardiol, 2007, 49(22): 2151-2159.
  • 5UDELSON JE, ORLANDI C, OUYANG J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: An international, multicenter, randomized, placebo- controlled trial[J]. J Am Coil Cardiol, 2008, 52( 19): 1540-1545.
  • 6KIDA K, SHIBAGAKI Y, TOMtNAGA N, et ol. Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study [J]. Clin Pharmacokinet, 2015, 54 (3) : 273-284.
  • 7KINUGAWA K, SATO N, INOMATA T, et all. Efficacy and safety of tolvaptan in heart failure patients with volume overload [J]. Circ J, 2014, 78(4) : 844-852.
  • 8ABDEL-QADIR HM, TU JV, YUN L, et ol. Diuretic dose and long- termoutcomes in elderly patients with heart failure after hospitalization[J]. Am Heart J, 2010, 160(2) : 264-271.
  • 9DOMANSKI M, NORMAN J, PITY B, et 01. Diuretic use, progressive heart failure, and death in patients in the Studies of Left Venticular Dysfunction (SOLVD) [J]. J Am Coll Cardiol, 2003, 42(4): 705-708.
  • 10FELKER GM, LEE KL, BULL DA, et 01. Diuretic strategies in patients with acute decompensated heart failure [J]. N Engl J Med, 2011, 364(9): 797-805.

共引文献75

同被引文献109

引证文献12

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部